

Development of multi-functioning lead compounds for lymphedema



OTHERS	Lead
Product Type	Chemical Product
Indication	Lymphedema
Target	Nrf 2 (Nuclear factor erythroid-2-related factor 2) signaling pathway
MoA(Mechanism of Action)	It activates the Nrf2 and prevents the development of Lymphedema
Competitiveness	<ol style="list-style-type: none"> 1. First-in-Class 2. Competitor is developing drugs that control only some of the major factors(anti-inflammatory, anti-fibrotic and anti-adipogenic effect) of lymphedema. However, in this project, multi-functioning lead compounds that effectively control all of the major factor will be developed.
Development Stage	Lead
Route of Administration	Oral administration